Shield Therapeutics (GB:STX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shield Therapeutics reports significant growth in Q3 2024, with ACCRUFeR® net revenues reaching $7.2 million, a notable increase driven by prescription demand in the US. The company is strengthening its financial position by expanding accounts receivable financing to $15 million and implementing a 10% cost-saving plan. Additionally, Shield is in discussions with AOP Health for a potential $10 million equity investment to support its goal of achieving positive cash flow by the end of 2025.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.